{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Pharmacologic Substance[C1909]|Immunotherapeutic Agent" in comments (approximate match)
Status:
US Approved Rx
(1990)
First approved in 1990
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1996)
First approved in 1981
Source:
BLA103676
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2001)
First approved in 1977
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(2000)
First approved in 1974
Class:
STRUCTURALLY DIVERSE
Status:
US Approved Rx
(1998)
First approved in 1971
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT01436968: Phase 3 Interventional Active, not recruiting Prostate Cancer
(2011)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00040092: Phase 3 Interventional Completed Pancreatic Cancer
(2002)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT00010452: Phase 2/Phase 3 Interventional Completed Lymphatic Malformations
(2000)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
ANTIVENIN (MICRURUS FULVIUS) by WYETH PHARMACEUTICALS INC
(1967)
Source URL:
First approved in 1967
Source:
ANTIVENIN (MICRURUS FULVIUS) by WYETH PHARMACEUTICALS INC
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
BLA125034
(2003)
Source URL:
First approved in 2003
Source:
BLA125034
Source URL:
Class:
STRUCTURALLY DIVERSE